T-Bird Pharma Inc. Announces Partnership with Medna Biosciences Inc.

VICTORIA, BC, March 11, 2015 /CNW/ - T-Bird Pharma Inc., a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP") to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR"), is pleased to announce that it, together with certain of its shareholders, has entered into an agreement with Medna Biosciences Inc. (“Medna”) whereby Medna will acquire (the “Escrow Transfer”) a total of 20,156,790 common shares of T-Bird (45% of the Company’s issued shares) from five of its founding shareholders, including its former CEO and CFO, at a price of $0.21 per share. This block of shares is currently held in escrow and the shares will be transferred within escrow and remain bound by those terms and conditions. The Escrow Transfer is subject to TSX-V approval. Medna is a privately held company building a portfolio of diversified assets in the medical marijuana space....

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.tbirdpharma.com/